<DOC>
	<DOCNO>NCT02592395</DOCNO>
	<brief_summary>The purpose study see well electrochemotherapy work treat people Stage III pancreatic adenocarcinoma . Electrochemotherapy treatment combine electroporation chemotherapy administration . Electroporation use electric current produce hole pancreatic tumor , cause tumor cell die take high concentration administer chemotherapy agent . This study test safety look effect electrochemotherapy treatment stage III pancreatic adenocarcinoma . This study also help find safe effective amount electroporation voltage apply type tumor .</brief_summary>
	<brief_title>Study FOLFIRINOX Electrochemotherapy Treatment Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>This phase I dose escalation trial use 3 + 3 dose escalation scheme evaluate maximum tolerated field strength dose administer irreversible electroporation combination chemotherapy . During first cycle chemotherapy , patient receive electroporation primary pancreatic tumor prior administration chemotherapy FOLFIRINOX . The schedule administration FOLFIRINOX administer per standard care . The investigator use non-invasive dynamic magnetic resonance image magnetic resonance spectroscopy detect describe change within tumor . Safety determine assess number class three high toxicity event cohorts 6 patient progressively high electroporation voltage . The maximum tolerated dose ( MTD ) define one voltage level less voltage two patient six total patient class three high toxicity event .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Histologically cytologically proven pancreatic carcinoma safely accessible percutaneous method ; Locally advance unresectable pancreatic adenocarcinoma ; At least one measurable lesion accord Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion ( long diameter &gt; =20 mm use conventional technique &gt; =10 mm spiral CT MRI scan ) ; WHO performance status ( PS ) &lt; 2 Eastern Cooperative Oncology Group &lt; 2 ; Age &gt; 18 ; Life expectancy &gt; 3 month ; No history gastric esophageal varix ; No active , uncontrolled infection ; All patient must adequate physiologic ( hematologic , renal hepatic ) reserve evidence : neutrophil count &gt; 1500/mL ; platelet count &gt; 100,000/mL ; serum creatinine &lt; 1.5x upper limit normal ( ULN ) value ; serum glutamicpyruvic transaminase ( SGPT ) &lt; 2.5 x ULN bilirubin &lt; 1.5 x ULN function Pain biliary obstruction control start study Absence psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule ; Women childbearing potential ( define sexually mature woman 1 ) undergone hysterectomy [ surgical removal uterus ] bilateral oophorectomy [ surgical removal ovary ] 2 ) naturally postmenopausal last 24 consecutive month ) must negative pregnancy test prior start therapy . Men woman childbearing potential must willing use effective contraceptive treatment reasonable period thereafter . Prior chemotherapy FOLFIRINOX ; Prior history pancreatic electroporation ; Untreatable contrast allergy ; History allergy hypersensitivity gemcitabine , nabpaclitaxel , excipients ; Presence metal biliary stent ; Psychosis seizures ; Evidence serious gastrointestinal bleeding bowel obstruction ; Pregnant lactate woman ; Women childbearing potential use adequate protection ; Inability tolerate MRI imaging</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>pancreatic adenocarcinoma</keyword>
	<keyword>electrochemotherapy</keyword>
	<keyword>electroporation</keyword>
	<keyword>radiogenomics</keyword>
	<keyword>image</keyword>
	<keyword>magnetic resonance spectroscopy</keyword>
</DOC>